Systemic amyloidosis refers to a group of rare diseases caused by an abnormal build-up of amyloid protein in the body's organs and tissues. The deposition of amyloid fibrils disrupts the normal organ structure and function. Some of the common symptoms include edema, heart and kidney dysfunction. The major types of systemic amyloidosis include AL amyloidosis, AA amyloidosis and ATTR amyloidosis. Currently, the treatment options are limited and aim to remove amyloid deposits, reduce amyloid protein production or correct the abnormalities that cause amyloid accumulation.

The Global Systemic Amyloidosis Therapeutic Market is estimated to be valued at USD 6.19 Bn in 2024 and is expected to reach USD 10.99 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.9% from 2024 to 2031.

- Key players operating in the systemic amyloidosis therapeutic market are Pfizer Inc, Prothena Corporation, Alnylam Pharmaceuticals, Nevrotherapies and Bausch Health Companies.

- The rising prevalence of ATTR Systemic Amyloidosis Therapeutic Market and AL amyloidosis disorders globally is expected to drive the market growth. According to the National Organization for Rare Diseases (NORD), AL amyloidosis affects around 4,500 people in the United States each year.

- Technological advancements including development of gene silencing RNA interference therapies and stem cell therapies provide non-toxic treatment alternatives to currently approved chemotherapies and medicines. Several drugs in pipeline aim to reduce amyloid protein synthesis or promote clearance through RNA interference.

Market Trends
- Increasing research in cell and gene therapies: Many biotech companies are exploring cell-based therapies involving stem cells and gene therapies using RNA interference to treat amyloidosis. Notably, Alnylam Pharmaceuticals is conducting trials for lumasiran, an RNAi therapeutic targeting ATTR amyloidosis.

- Growth in amyloid protein diagnostic tests: Technological advancements are aiding the development of novel diagnostic tests to detect disease-causing amyloid proteins in bodily fluids or tissues. This helps in early diagnosis and timely management of the condition.

Market Opportunities
- Untapped emerging markets: Developing regions like Asia Pacific and Middle East provide lucrative opportunities for amyloidosis drug manufacturers owing to increasing healthcare spending and improving access to diagnosis and treatment.

- Novel treatment approaches: Areas like anti-amyloid monoclonal antibodies, small molecule protein stabilizers and mRNA therapies holds promise for development of next-generation precision therapies.

Impact of COVID-19 on Systemic Amyloidosis Therapeutic Market:
The COVID-19 pandemic has negatively impacted the growth of systemic amyloidosis therapeutic market. As per various studies, the pandemic has delayed clinical trials and drug development activities. The lockdowns imposed by various governments disrupted the supply chain and led to postponement of non-emergency medical procedures. This hampered both drug development and treatment processes. However, with vaccination drives and relaxation of restrictions, the market is slowly recovering.

Key factors like resumption of clinical trials, focus on fast-tracking drug approvals and development of novel treatment options will help drive market growth post-pandemic. Telemedicine and digital health have also emerged as important aspects of care. This allows continuity of care while avoiding risks of infection. Biotech companies are collaborating to accelerate research on systemic amyloidosis. Given the growth in elderly population and rise in lifestyle diseases, this segment is likely to witness steady growth in the coming years.

In terms of value, Europe accounted for the largest share of systemic amyloidosis therapeutic market pre-COVID. Factors like high healthcare expenditure, presence of leading drug makers and advanced healthcare infrastructure supported market growth. However, Asia Pacific is estimated to be the fastest growing regional market post pandemic, primarily owing to increasing healthcare investments, growing medical tourism industry and rising economic stability. China and India especially are expected to provide lucrative opportunities driven by large patient pools and improving accessibility and affordability of treatments.

Get more insights on: Systemic Amyloidosis Therapeutic Market

Get this Report in Japanese Language: 全身性アミロイドーシス治療市場

Get this Report in Korean Language: 전신성 아밀로이드증 치료 시장

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)